Sunshine Heart C-Pulse implantable heart assist device passes 5-year durability testing
The Polymer Technology Group (PTG) indicated that its customer, Sunshine Heart Inc., has passed the five-year milestone on durability-testing of its C-Pulse implantable heart assist device. C-Pulse is designed to be a non-blood-contacting heart assist therapy for treating patients with moderate to severe heart failure, a condition in which the heart progressively loses its ability to efficiently pump blood throughout the body. C-Pulse includes two polymers from PTG.

-
FDA Approves For Permanent Treatment Of Advanced Heart Failure Assist Device Pioneered By Texas Heart Institute At St. Luke’s Episcopal Hospital
FDA gives unconditional IDE approval to Berlin Heart’s EXCOR
HeartWare files for destination therapy IDE
FDA Looking Into Heart-Related Death Risk of Benicar
New use of Boston Scientific devices backed by FDA
